|
Jun 26
|
Revive Therapeutics Nears Completion of Nerve Agent Countermeasure Study with Canadian DND
|
|
Jun 26
|
Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity
|
|
Apr 21
|
Revive Therapeutics Announces Proposed Shares for Debt Transaction
|
|
Apr 2
|
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
|
|
Jan 10
|
Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
|
|
Dec 20
|
Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
|
|
Dec 18
|
Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
|